Deliver long-lasting topical flea and tick protection for your canine patients.
Benefits of BRAVECTO® Topical Solution for Dogs
Fast-acting and long-lasting
flea and tick protection
- Provides up to 12 weeks* of flea and tick protection in just one dose
- Extended-duration helps reduce potential gaps in protection
- Less likelihood of forgetting medication with up to two-thirds less dosing needed than monthly treatments
- Available by veterinary prescription only
Easy-to-use formula
- Easy to administer with Twist’n’Use™ applicator
- Applied topically but works systemically1
- Helpful for dogs who do not like oral medication
- Resists repeated swimming/bathing for its full 12-week* dosing period1
Trusted active ingredient
- Fluralaner, an ectoparasiticide belonging to the isoxazoline group
- Systemically active against fleas and ticks for 12 weeks*
- Starts killing within 2 hours after administration1 for quick flea control
Indications
BRAVECTO Topical Solution for Dogs kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick)] for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.
BRAVECTO Topical Solution for Dogs is also indicated for the treatment and control of Amblyomma americanum (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater.
Prescribe BRAVECTO based on the patient’s weight1
More continuous coverage with 12 long weeks* of protection
Make every dose last ~3X* longer with BRAVECTO Topical Solution for Dogs1
*BRAVECTO (fluralaner topical solution) for Dogs kills fleas, prevents flea infestations, and kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks. BRAVECTO Topical Solution for Dogs also kills lone star ticks for 8 weeks.
BRAVECTO: Persistent efficacy against fleas1-3
Fast and persistent flea protection for dogs
12-WEEK FLEA PROTECTION FOR DOGS1,2
The flea control efficacy of BRAVECTO was evaluated in a 12-week multicenter, clinical field study.2
- Over 12 weeks, there were 3-6x more flea-free dogs with BRAVECTO than 3 monthly doses of Frontline® Plus4
- One dose of BRAVECTO also reduced fleas by ≥99.8% for 12 weeks1,5
- 86%-100% of dogs with signs attributed to flea allergy dermatitis (FAD) had resolution of the following signs by the end of the study2:
- Erythema, papules, crusts, alopecia, scales, excoriation
The difference of 12-week tick protection1,2
Long-lasting tick protection for dogs
12-WEEK CLINICAL EVALUATION RESULTS
BRAVECTO efficacy was evaluated in a 12-week clinical field study. Results found that BRAVECTO has a ≥93.3% effectiveness for 12 weeks against Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick) and ≥90% effectiveness for 8 weeks against Amblyomma americanum (lone star tick).1 BRAVECTO was also shown to reduce exposure to ticks, which can carry tick-borne diseases.
‡ 72-hour post infestation
§ Lone star tick results at 12 weeks from 3 studies ranged from 69.5% to 92.0% efficacy
BRAVECTO is proven safe
No known contraindications for BRAVECTO Chews for Dogs and BRAVECTO Topical Solution for Dogs.1,6
No problems reported in field trials in dogs that received BRAVECTO concurrently with other commonly used medication.1,6
BRAVECTO has not been shown to be effective for 12 weeks duration in puppies less than 6 months of age.6
In field studies and safety studies, no dogs experienced serious adverse events.1,2,6,7
In margin of safety study, puppies were dosed at three 8-week intervals.
BRAVECTO has been evaluated for use in breeding, pregnant, and lactating female dogs.1,6 BRAVECTO is safe to use and efficacious in adult dogs and puppies over 6 months of age and weighing 4.4 pounds or greater.1,6 It has been tested and found safe in puppies at least 8 to 9 weeks of age at 5x the clinical dose.1,6,8 No adverse effects with BRAVECTO Chews for Dogs in MDR-1 gene-deficient collies at 3x the recommended dose.9
Discover the 12-week* difference
Ask your Merck Animal Health representative or reach out to us for more information about BRAVECTO topical flea and tick treatment for your hospital.
We’ll answer any questions and help you start prescribing BRAVECTO for the dogs in your care.
Frequently Asked Questions about BRAVECTO Topical Solution for Dogs
In well-controlled laboratory studies, BRAVECTO Topical Solution for Dogs killed fleas and reduced the numbers of live fleas on dogs by >99% and 100% within 24 and 48 hours, respectively, postinfestation for 12 weeks. BRAVECTO Topical Solution for Dogs demonstrated ≥93.3% effectiveness against Dermacentor variabilis, Ixodes scapularis, and Rhipicephalus sanguineus 48 hours postinfestation for 12 weeks and ≥90% effectiveness against Amblyomma americanum 72 hours postinfestation for 8 weeks.1
Both BRAVECTO Topical Solution for Dogs and BRAVECTO Chews provide effective, fast, and extended-duration protection for dogs for 12 weeks.* Talk with pet owners about which option works better for their situation and their dog to help enhance compliance.
For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318.
This site is intended for veterinary professionals. Visit our website for pet owners.
* BRAVECTO (fluralaner topical solution) for Dogs kills fleas, prevents flea infestations, and kills ticks (black-legged tick, American dog tick, and brown dog tick) for 12 weeks. BRAVECTO Topical Solution for Dogs also kills lone star ticks for 8 weeks.
Important Safety Information
BRAVECTO 1-MONTH (fluralaner) Chews: indicated for dogs 8 weeks of age and older. The most commonly reported adverse reactions include itching, diarrhea, vomiting, decreased appetite, elevated ALT, lethargy, and weight loss. BRAVECTO 1-MONTH is not effective against A americanum in puppies less than 6 months of age. BRAVECTO (fluralaner) Chews for Dogs: The most commonly reported adverse reactions include vomiting, lethargy, diarrhea, anorexia, and pruritus. In some cases, adverse events have been reported following use in breeding females. BRAVECTO (fluralaner topical solution) for Dogs: The most commonly reported adverse reactions include vomiting, hair loss, diarrhea, lethargy, decreased appetite, and moist dermatitis/rash.
BRAVECTO Chews and Topical Solution for Dogs have not been shown to be effective for 12-weeks’ duration in puppies less than 6 months of age. BRAVECTO Chews and Topical Solution for Dogs are not effective against the lone star tick beyond 8 weeks of dosing. BRAVECTO Topical Solution for Dogs is for topical use only. Avoid oral ingestion.
All BRAVECTO products contain fluralaner, which is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders.
References
- BRAVECTO® Topical Solution for Dogs. Product label. Merck Animal Health; 2019
- Freedom of Information Summary, NADA 141-459. July 20, 2016.
- Taenzler J, Wengenmayer C, Williams H, et al. Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs. Parasit Vectors. 2014;7:567. doi:10.1186/s13071-014-0567-6
- Data on file. Merck Animal Health.
- Meadows C, Guerino F, Sun F. A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling canine flea infestations. Parasit Vectors. 2017;10:36. doi:10.1186/s13071-017-1971-5
- BRAVECTO® Chews for Dogs. Product label. Merck Animal Health; 2022.
- Freedom of Information Summary, NADA 141-426. May 25, 2014.
- Walther FM, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner chewable tablets (Bravecto™), a novel systemic antiparasitic drug, in dogs after oral administration. Parasit Vectors. 2014;7:87. doi:10.1186/1756-3305-7-87
- Walther FM, Paul AJ, Allan MJ, Roepke RKA, Nuernberger MC. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) collies after oral administration. Parasit Vectors. 2014;7:86. doi: 10.1186/1756-3305-7-86
All trademarks are the property of their respective owners.